Kory James Wentworth has sold stock and made no open-market buys since Dec 2018

Kory James Wentworth is the Chief Financial Officer and Treasurer of Entrada Therapeutics, Inc. (NASDAQ: TRDA), a clinical-stage biotechnology company developing intracellular biologics using its proprietary cell-penetrating miniature protein (CPMP) platform.( A Certified Public Accountant (CPA) in Connecticut, he holds a BS in Accounting from Susquehanna University.(

Wentworth's career includes prior roles as VP Finance and Treasurer, Principal Accounting Officer at bluebird bio, where he managed accounting, tax, treasury, finance operations, and reporting, building a global team for expansion and product launches.( Before that, he spent nine years at Alexion Pharmaceuticals, rising to Executive Director and Corporate Controller, and earlier held audit positions at PricewaterhouseCoopers LLP for six years.( Recently, as Entrada CFO, he sold shares in multiple transactions in early March 2026, totaling 24,465 shares for approximately $312,000, retaining 132,898 shares valued at about $1.73 million.(

Written by Perplexity from public sources.